Latest news
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 14:18:19 GMTSNDX: Q2 revenue surged 92% year-over-year, driven by strong Revuforj and Niktimvo growth - TradingViewTradingView · Tue, 04 Aug 2026 23:20:53 GMTSyndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand - TradingViewTradingView · Tue, 04 Aug 2026 20:12:06 GMTPhil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Trajectory and Potential $2B Peak U.S. Sales - TipRanksTipRanks · Tue, 04 Aug 2026 07:00:00 GMTSyndax Pharmaceuticals (SNDX): Can Revuforj And Niktimvo Power The Next Phase Of Growth? - RTTNewsRTTNews · Mon, 03 Aug 2026 11:36:00 GMT